Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer.
Saatci O, Kaymak A, Raza U, Ersan PG, Akbulut O, Banister CE, Sikirzhytski V, Tokat UM, Aykut G, Ansari SA, Dogan HT, Dogan M, Jandaghi P, Isik A, Gundogdu F, Kosemehmetoglu K, Dizdar O, Aksoy S, Akyol A, Uner A, Buckhaults PJ, Riazalhosseini Y, Sahin O. Saatci O, et al. Among authors: ersan pg. Nat Commun. 2020 May 15;11(1):2416. doi: 10.1038/s41467-020-16199-4. Nat Commun. 2020. PMID: 32415208 Free PMC article.
The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer.
Raza U, Saatci Ö, Uhlmann S, Ansari SA, Eyüpoğlu E, Yurdusev E, Mutlu M, Ersan PG, Altundağ MK, Zhang JD, Doğan HT, Güler G, Şahin Ö. Raza U, et al. Among authors: ersan pg. Oncotarget. 2016 Aug 2;7(31):49859-49877. doi: 10.18632/oncotarget.10489. Oncotarget. 2016. PMID: 27409664 Free PMC article.
Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.
Mishra RR, Belder N, Ansari SA, Kayhan M, Bal H, Raza U, Ersan PG, Tokat ÜM, Eyüpoğlu E, Saatci Ö, Jandaghi P, Wiemann S, Üner A, Cekic C, Riazalhosseini Y, Şahin Ö. Mishra RR, et al. Among authors: ersan pg. Clin Cancer Res. 2018 Apr 15;24(8):1987-2001. doi: 10.1158/1078-0432.CCR-17-2776. Epub 2018 Jan 31. Clin Cancer Res. 2018. PMID: 29386221
Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers.
Siddiqui A, Gollavilli PN, Schwab A, Vazakidou ME, Ersan PG, Ramakrishnan M, Pluim D, Coggins S, Saatci O, Annaratone L, Hm Schellens J, Kim B, Asangani IA, Rasheed SAK, Marchiò C, Sahin O, Ceppi P. Siddiqui A, et al. Among authors: ersan pg. Cell Death Differ. 2019 Nov;26(11):2223-2236. doi: 10.1038/s41418-019-0289-6. Epub 2019 Feb 8. Cell Death Differ. 2019. PMID: 30737477 Free PMC article.
Systems-level Analysis Reveals Multiple Modulators of Epithelial-mesenchymal Transition and Identifies DNAJB4 and CD81 as Novel Metastasis Inducers in Breast Cancer.
Uretmen Kagiali ZC, Sanal E, Karayel Ö, Polat AN, Saatci Ö, Ersan PG, Trappe K, Renard BY, Önder TT, Tuncbag N, Şahin Ö, Ozlu N. Uretmen Kagiali ZC, et al. Among authors: ersan pg. Mol Cell Proteomics. 2019 Sep;18(9):1756-1771. doi: 10.1074/mcp.RA119.001446. Epub 2019 Jun 20. Mol Cell Proteomics. 2019. PMID: 31221721 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33451533
Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors.
Wang L, Londono LM, Cowell J, Saatci O, Aras M, Ersan PG, Serra S, Pei H, Clift R, Zhao Q, Phan KB, Huang L, LaBarre MJ, Li X, Shepard HM, Deaglio S, Linden J, Thanos CD, Sahin O, Cekic C. Wang L, et al. Among authors: ersan pg. Cancer Res. 2021 Jun 15;81(12):3319-3332. doi: 10.1158/0008-5472.CAN-21-0340. Epub 2021 Apr 16. Cancer Res. 2021. PMID: 33863778
12 results